The Scientific World Journal

Research Article

Population Pharmacokinetics of Vancomycin in Thai Patients

Table 1

Summary of demographic and clinical characteristics of the patients in the modeling group and the validation group.
CharacteristicsModeling groupValidation groupP valuea
Number of patients21234NDb
Total number of vancomycin levels39168NDb
Average number of vancomycin level per patient1.842.00NDb
Sex distributionMale: 112 (52.83%);
Female: 100 (47.17%)		Male: 12 (35.29%);
Female: 22 (64.71%)		0.058
Age, in years (mean ± SD) 6 6 . 6 2 ± 1 8 . 3 8 7 0 . 2 4 ± 1 8 . 6 1 0.288
Total body weight, in kg (mean ± SD) 5 7 . 6 4 ± 1 1 . 6 2 5 5 . 8 1 ± 1 2 . 2 0 0.201
Serum creatinine, in mg/dL (mean ± SD) 3 . 1 2 ± 2 . 9 2 2 . 7 0 ± 2 . 8 1 0.421
Blood urea nitrogen, in mg/dL (mean ± SD) 4 0 . 2 5 ± 2 5 . 1 5 4 6 . 4 1 ± 4 0 . 0 6 0.410
Creatinine clearance by Cockcroft-Gault equation, in mL/min (mean ± SD) 3 5 . 0 7 ± 2 9 . 8 3 3 5 . 5 0 ± 3 0 . 6 1 0.939
Creatinine clearance by MDRD4 equation, in mL/min/1.73 m2 (mean ± SD) 4 4 . 0 8 ± 3 6 . 7 1 4 5 . 3 6 ± 3 6 . 4 3 0.85
Albumin, in g/L (mean ± SD) 2 5 . 9 3 ± 7 . 3 1 2 8 . 7 9 ± 7 . 5 3 0.047*
AST, in U/L (mean ± SD) 8 7 . 0 8 ± 1 7 7 . 7 1 3 4 6 . 5 2 ± 1 6 2 0 . 1 1 0.396
ALT, in U/L (mean ± SD) 8 3 . 2 7 ± 1 5 7 . 9 3 1 5 6 . 1 7 ± 5 7 9 . 6 0 0.506
Total bilirubin, in mg/dL (mean ± SD) 3 . 2 2 ± 7 . 3 9 1 . 8 5 ± 4 . 0 4 0.329
Direct bilirubin, in mg/dL (mean ± SD) 2 . 3 8 ± 5 . 9 4 1 . 1 5 ± 2 . 9 0 0.074
Ascites (yes/no/unknown)43/169/05/26/30.587
Concomittant medication (yes/no/unknown)
 Aminoglycosides27/185/01/30/30.121
 Amphotericin B12/200/00/31/30.174
 NSAIDs20/192/03/27/40.921
 Dopamine33/179/02/28/40.195
 Dobutamine9/203/00/30/40.250
 Adrenaline/noradrenaline24/188/02/28/40.441
 Furosemide77/135/015/15/40.149
aDifferences between the modeling and validation group were considered to reach statistical significance when 𝑃 < 0 . 0 5 ; bNot determined; *statistically significant.